User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
Executive Summary
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles
You may also be interested in...
DTC User Fees Rejected By House Approps Panel As FDA Safety Funds Get Boost
The House Appropriations Committee opted for using federal money, rather than fees from industry, to finance speedier FDA review of direct-to-consumer television ads when it approved a $1.7 billion fiscal year 2008 funding package for the agency July 19
DTC User Fees Rejected By House Approps Panel As FDA Safety Funds Get Boost
The House Appropriations Committee opted for using federal money, rather than fees from industry, to finance speedier FDA review of direct-to-consumer television ads when it approved a $1.7 billion fiscal year 2008 funding package for the agency July 19
DTC Review Will Cost Industry $83,000 Per Ad Under FDA’s Final PDUFA Plan
FDA expects to charge companies $83,000 per advertisement under a pre-review program included as part of the agency's proposal for renewal of the prescription drug user fee program